Table 5.
Subjects clinical symptoms and laboratory finding before and after the treatment.
| Nano-curcumin group (n = 28) |
Placebo group (n = 23) |
||||||
|---|---|---|---|---|---|---|---|
| Before (n = 30) | After (n = 28) | P value | Before (n = 30) | After (n = 23) | P value | ||
| Fever | <37.3 °C | 3 (%10) | 21 (75%) | <0.001 | 1 (%3.3) | 2 (7%) | 0.546 |
| 37.3–38.0 °C | 11 (%36.6) | 7 (25%) | 14 (%46.6) | 10 (43%) | |||
| 38.1–39.0 °C | 9 (%30) | 0 (0%) | 9 (%30) | 8 (34%) | |||
| >39.0 °C | 7 (%23.3) | 0 (0%) | 6 (%20) | 4 (13%) | |||
| Cough | 18 (%60) | 3 (10%) | <0.001 | 20 (%66.6) | 6 (26%) | 0.038 | |
| Headache | 2 (%6.6) | 0 (0%) | – | 3 (%10) | 2 (8%) | – | |
| Dyspnea | 8 (%26.6) | 1 (3%) | <0.001 | 7 (%23.3) | 5 (21%) | 0.124 | |
| White blood cell count, × 109/L | <4 | 8 (%26.6) | 3 (10%) | <0.001 | 7 (%23.3) | 4 (17%) | 0.223 |
| 4–10 | 12 (%40) | 20 (71%) | 14 (%46.6) | 13 (56%) | |||
| >10 | 10 (%33.3) | 5 (17%) | 9 (%30) | 6 (26%) | |||
| Lymphocyte count, × 109/L | <1·0 | 20 (%66.6) | 7 (25%) | <0.001 | 18 (%60) | 9 (39%) | 0.043 |
| ≥1·0 | 10 (%33.3) | 21 (75%) | 12 (%40) | 14 (60%) | |||
| Platelet count, × 109/L | <100 | 19 (%63.3) | 6 (21%) | <0.001 | 21 (%70) | 15 (65%) | 0.367 |
| ≥100 | 11 (%36.6) | 22 (78%) | 9 (%30) | 8 (34%) | |||
| Creatinine, μmol/L | ≤133 | 25 (%83.3) | 27 (96%) | <0.0001 | 27 (%90) | 19 (82%) | |
| >133 | 5 (%16.6) | 1 (3%) | 3 (%10) | 4 (17%) | 0.381 | ||
| Lactate dehydrogenase, U/L | ≤245 | 20 (%66.6) | 26 (92%) | <0.0001 | 19 (%63.3) | 16 (69%) | |
| >245 | 10 (%33.3) | 2 (56%) | 11 (%36.6) | 7 (30%) | 0.184 | ||
| Bilateral involvement of chest radiographs | 28 (%93.3) | 9 (32%) | <0.0001 | 28 (%93.3) | 12 (52%) | 0.011 | |
| mechanical ventilation | 3 (10%) | 0 (0%) | – | 2 (6%) | 0 (0%) | – | |